{"hands_on_practices": [{"introduction": "Understanding a complex metabolic network like cholesterol synthesis often relies on clever experimental design to trace its logic. This practice challenges you to think like an experimental biochemist, using a \"rescue\" experiment to deduce the site of action of an inhibitor. By predicting how different downstream metabolites restore pathway function, you will solidify your understanding of the overall architecture of isoprenoid biosynthesis, particularly its critical branch point separating sterol and non-sterol products [@problem_id:2550161].", "problem": "A hepatocyte model is used to interrogate the logic of the cholesterol biosynthetic pathway and its regulation. Consider the following established bases: (i) $3$-hydroxy-$3$-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the reduction of $3$-hydroxy-$3$-methylglutaryl coenzyme A to mevalonate; (ii) mevalonate is the committed precursor to all isoprenoids via isopentenyl pyrophosphate and dimethylallyl pyrophosphate, leading to farnesyl pyrophosphate and geranylgeranyl pyrophosphate that feed both the sterol branch (through squalene to cholesterol) and nonsterol branches (including coenzyme Q, dolichol phosphate, and protein prenylation); (iii) pharmacological inhibition of an enzyme can be bypassed if an exogenous metabolite enters downstream of the inhibited step, whereas a metabolite entering after a pathway branch will not restore products of branches that diverged upstream of its entry point.\n\nHepatocytes are treated with a competitive HMGCR inhibitor (a statin). Two rescue conditions are tested: supplementation with mevalonate and supplementation with squalene. The readouts include cellular cholesterol, coenzyme Q, dolichol phosphate, and the accumulation of unprenylated small GTPases.\n\nWhich of the following patterns of outcomes and inference about the inhibitor’s site of action is most consistent with the pathway logic above?\n\nA. Mevalonate restores cholesterol, coenzyme Q, dolichol phosphate, and prevents accumulation of unprenylated GTPases; squalene restores only cholesterol but not coenzyme Q, dolichol phosphate, or prenylation; conclusion: the inhibitor acts at HMGCR upstream of mevalonate formation.\n\nB. Mevalonate and squalene both fully restore cholesterol, coenzyme Q, dolichol phosphate, and prenylation; conclusion: the inhibitor acts downstream of squalene.\n\nC. Squalene restores both cholesterol and prenylation, whereas mevalonate restores only prenylation but not cholesterol; conclusion: the inhibitor acts at squalene synthase.\n\nD. Mevalonate restores cholesterol but not prenylation, coenzyme Q, or dolichol phosphate; squalene restores prenylation but not cholesterol; conclusion: the inhibitor acts at lanosterol synthase.\n\nE. Mevalonate rescues coenzyme Q and prenylation but fails to rescue cholesterol; squalene rescues cholesterol but not coenzyme Q or prenylation; conclusion: the inhibitor competes at squalene epoxidase.", "solution": "The problem statement must first be validated for its scientific and logical integrity.\n\n**Step 1: Extraction of Givens**\n- The system is a hepatocyte model.\n- The pathway is the cholesterol biosynthetic pathway.\n- An enzyme, $3$-hydroxy-$3$-methylglutaryl coenzyme A reductase (HMGCR), catalyzes the conversion of $3$-hydroxy-$3$-methylglutaryl coenzyme A (HMG-CoA) to mevalonate.\n- Mevalonate is the precursor to all isoprenoids, including those in the sterol branch (leading to cholesterol) and non-sterol branches.\n- The pathway proceeds from mevalonate to isopentenyl pyrophosphate and dimethylallyl pyrophosphate, then to farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).\n- At this point, the pathway branches:\n    - The sterol branch proceeds from FPP to squalene, and then to cholesterol.\n    - The non-sterol branches utilize FPP and GGPP to synthesize products such as coenzyme Q, dolichol phosphate, and for protein prenylation.\n- A principle of pathway analysis is stated: inhibition can be bypassed by supplying a metabolite downstream of the block. A metabolite added after a branch point will not restore products of the diverged branch.\n- An experiment is conducted where hepatocytes are treated with a competitive HMGCR inhibitor (a statin).\n- Two rescue experiments are performed: supplementation with exogenous mevalonate and supplementation with exogenous squalene.\n- The measured outputs are: cellular cholesterol, coenzyme Q, dolichol phosphate, and the accumulation of unprenylated small GTPases (a marker for failed protein prenylation).\n\n**Step 2: Validation of the Problem Statement**\nThe problem is scientifically grounded. The description of the cholesterol biosynthesis pathway, the function of HMGCR, the role of mevalonate as a common precursor, the branching at FPP/GGPP into sterol and non-sterol pathways, and the mechanism of action of statins as HMGCR inhibitors are all well-established facts in biochemistry. The experimental design using an inhibitor and rescue with downstream metabolites is a standard and logical method for elucidating metabolic pathways. The problem is well-posed, objective, and contains sufficient information to deduce a unique answer. No scientific or logical flaws are present.\n\n**Verdict: The problem statement is valid.**\n\n**Derivation of the Correct Outcome**\n\nThe problem states that a statin, a known competitive inhibitor of HMGCR, is used. This block occurs at the very beginning of the isoprenoid synthesis pathway.\n\n**Effect of the HMGCR inhibitor (statin):**\nHMGCR catalyzes the reaction: $$ \\text{HMG-CoA} \\xrightarrow{\\text{HMGCR}} \\text{Mevalonate} $$\nInhibition by a statin blocks the production of mevalonate. As mevalonate is the committed precursor for all subsequent products, the synthesis of cholesterol, coenzyme Q, dolichol phosphate, and the substrates for protein prenylation (FPP, GGPP) will all be severely diminished. This will lead to an accumulation of unprenylated GTPases.\n\n**Rescue with Mevalonate:**\nMevalonate is introduced into the system exogenously. It enters the pathway downstream of the HMGCR-catalyzed step.\n$$ \\text{HMG-CoA} \\xrightarrow{\\text{Statin Block}} \\diagup \\! \\! \\! \\! \\! \\! \\rightarrow \\text{Mevalonate (added)} \\rightarrow \\text{...} \\rightarrow \\text{FPP/GGPP} \\rightarrow \\begin{cases} \\text{Squalene} \\rightarrow \\text{Cholesterol} \\\\ \\text{Non-sterol products (CoQ, etc.)} \\\\ \\text{Protein prenylation} \\end{cases} $$\nSince mevalonate is the precursor to the common intermediate FPP/GGPP from which all branches diverge, its supplementation will bypass the statin block and restore flux through both the sterol and non-sterol pathways. Therefore, synthesis of cholesterol, coenzyme Q, and dolichol phosphate will be restored, and protein prenylation will proceed, thus preventing the accumulation of unprenylated GTPases.\n\n**Rescue with Squalene:**\nSqualene is introduced into the system exogenously. It is an intermediate in the sterol-specific branch of the pathway, formed from FPP and located downstream of the FPP/GGPP branching point.\n$$ \\text{Mevalonate} \\xrightarrow{\\text{Statin Block}} \\diagup \\! \\! \\! \\! \\! \\! \\rightarrow \\text{...} \\rightarrow \\text{FPP/GGPP} \\rightarrow \\begin{cases} \\text{Squalene (added)} \\rightarrow \\text{Cholesterol} \\\\ \\text{Non-sterol products (synthesis blocked)} \\\\ \\text{Protein prenylation (synthesis blocked)} \\end{cases} $$\nAccording to the problem's stated principle (iii), squalene supplementation will only restore the synthesis of products downstream of its entry point. Thus, it will restore cholesterol synthesis. However, it cannot be converted back to FPP or GGPP, so it cannot rescue the non-sterol branches. Synthesis of coenzyme Q and dolichol phosphate will remain inhibited, and protein prenylation will not be restored, leading to continued accumulation of unprenylated GTPases.\n\n**Summary of Expected Results:**\n- **Mevalonate rescue:** Restores cholesterol, coenzyme Q, dolichol phosphate, and protein prenylation.\n- **Squalene rescue:** Restores only cholesterol.\n- **Conclusion:** These results are consistent with the inhibitor acting at HMGCR, a point upstream of mevalonate and the FPP/GGPP branch point.\n\n**Evaluation of Options**\n\n**A. Mevalonate restores cholesterol, coenzyme Q, dolichol phosphate, and prevents accumulation of unprenylated GTPases; squalene restores only cholesterol but not coenzyme Q, dolichol phosphate, or prenylation; conclusion: the inhibitor acts at HMGCR upstream of mevalonate formation.**\n- **Analysis:** The pattern of outcomes described in this option precisely matches the derived expectations based on the known pathway logic. The conclusion drawn from these outcomes is also correct: such a pattern confirms the site of action is upstream of the divergence of all isoprenoid products, which is the HMGCR step.\n- **Verdict:** Correct.\n\n**B. Mevalonate and squalene both fully restore cholesterol, coenzyme Q, dolichol phosphate, and prenylation; conclusion: the inhibitor acts downstream of squalene.**\n- **Analysis:** This is incorrect. Squalene cannot restore the non-sterol products as it enters the pathway after the branch point. Furthermore, if the inhibitor acted downstream of squalene, squalene supplementation would not restore cholesterol synthesis. The outcomes and conclusion are both inconsistent with biochemical principles.\n- **Verdict:** Incorrect.\n\n**C. Squalene restores both cholesterol and prenylation, whereas mevalonate restores only prenylation but not cholesterol; conclusion: the inhibitor acts at squalene synthase.**\n- **Analysis:** This is incorrect. Squalene cannot restore prenylation. Mevalonate, as the common precursor, should restore both cholesterol and prenylation. If the inhibitor were at squalene synthase, mevalonate supplementation would indeed restore prenylation but not cholesterol. However, the problem explicitly states a statin (HMGCR inhibitor) is used. The described outcomes are inconsistent with each other and with the experimental premise.\n- **Verdict:** Incorrect.\n\n**D. Mevalonate restores cholesterol but not prenylation, coenzyme Q, or dolichol phosphate; squalene restores prenylation but not cholesterol; conclusion: the inhibitor acts at lanosterol synthase.**\n- **Analysis:** This describes a scenario that is the reverse of what should happen. Mevalonate should restore everything. Squalene should restore cholesterol but not the non-sterol products. The described outcomes are biochemically impossible under the given conditions.\n- **Verdict:** Incorrect.\n\n**E. Mevalonate rescues coenzyme Q and prenylation but fails to rescue cholesterol; squalene rescues cholesterol but not coenzyme Q or prenylation; conclusion: the inhibitor competes at squalene epoxidase.**\n- **Analysis:** This is incorrect. The outcome for mevalonate rescue is wrong; mevalonate should restore cholesterol if the only block is at HMGCR. The outcome described for mevalonate (rescuing non-sterol products but not cholesterol) would be consistent with a block in the sterol-specific branch (e.g., at squalene synthase or squalene epoxidase), but the problem states the inhibitor is a statin targeting HMGCR. The outcome for squalene is also contradictory; if the block were at squalene epoxidase (downstream of squalene), providing squalene would not rescue cholesterol.\n- **Verdict:** Incorrect.\n\nBased on this analysis, only option A is fully consistent with the established principles of cholesterol biosynthesis and its regulation by statins.", "answer": "$$\\boxed{A}$$", "id": "2550161"}, {"introduction": "After mapping the pathway, we now turn to its elegant regulation at the genetic level, which is masterfully governed by the SREBP-2 transcriptional feedback system. This exercise presents a thought experiment involving a mutation that disables the cholesterol-sensing ability of the escort protein SCAP [@problem_id:2550069]. Predicting the consequence of breaking this feedback loop will deepen your grasp of the molecular interactions between cholesterol, SCAP, and SREBP-2 that are fundamental to maintaining cellular homeostasis.", "problem": "A cultured mammalian cell line expresses Sterol Regulatory Element-Binding Protein 2 (SREBP-2), SREBP cleavage-activating protein (SCAP), and Insulin-induced gene proteins (Insig) at physiological levels. You are told that SCAP carries a point mutation within its sterol-sensing domain that abolishes SCAP’s ability to bind cholesterol, but leaves SCAP folding, the SCAP-SREBP-2 interaction, the MELADL COPII recognition motif, and Golgi processing by Site-1 and Site-2 proteases intact. No exogenous oxysterols are added; only cholesterol is varied. Cells are shifted into media driving different steady-state endoplasmic reticulum (ER) membrane cholesterol concentrations $[Ch]_{\\mathrm{ER}}$ spanning low to high. At steady state, the transcriptional output of SREBP-2 target genes (for example, $3$-hydroxy-$3$-methylglutaryl-CoA reductase and low-density lipoprotein receptor) is measured and reported as $E([Ch]_{\\mathrm{ER}})$.\n\nUsing only first principles and well-tested facts about the SREBP–SCAP–Insig pathway, predict the qualitative dependence of $E([Ch]_{\\mathrm{ER}})$ on $[Ch]_{\\mathrm{ER}}$ in this SCAP mutant. Choose the single best option that captures both the pattern and its mechanism.\n\nA. $E([Ch]_{\\mathrm{ER}})$ decreases monotonically with increasing $[Ch]_{\\mathrm{ER}}$ (high at low $[Ch]_{\\mathrm{ER}}$, low at high $[Ch]_{\\mathrm{ER}}$), due to cholesterol-dependent ER retention of SCAP-SREBP-2 by Insig.\n\nB. $E([Ch]_{\\mathrm{ER}}) \\approx E_{\\max}$ and is essentially independent of $[Ch]_{\\mathrm{ER}}$, because loss of cholesterol sensing prevents Insig-mediated ER retention and allows constitutive ER-to-Golgi trafficking and proteolytic activation of SREBP-2.\n\nC. $E([Ch]_{\\mathrm{ER}}) \\approx E_{\\min}$ and is essentially independent of $[Ch]_{\\mathrm{ER}}$, because SCAP cannot activate SREBP-2 without binding cholesterol.\n\nD. $E([Ch]_{\\mathrm{ER}})$ is high at low $[Ch]_{\\mathrm{ER}}$, partially reduced at intermediate $[Ch]_{\\mathrm{ER}}$, and strongly repressed only at very high $[Ch]_{\\mathrm{ER}}$, reflecting a right-shifted sterol dose–response via residual Insig-dependent retention.\n\nE. $E([Ch]_{\\mathrm{ER}})$ increases with increasing $[Ch]_{\\mathrm{ER}}$, because loss of feedback makes SREBP-2 more responsive to sterols.", "solution": "The supplied problem statement is subjected to rigorous validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\nThe following information is provided in the problem statement:\n- **System:** A cultured mammalian cell line.\n- **Expressed Proteins:** Sterol Regulatory Element-Binding Protein 2 (SREBP-2), SREBP cleavage-activating protein (SCAP), and Insulin-induced gene proteins (Insig) are expressed at physiological levels.\n- **SCAP Mutation:** A point mutation exists within the sterol-sensing domain (SSD) of SCAP.\n- **Consequences of SCAP Mutation:**\n    - SCAP's ability to bind cholesterol is abolished.\n    - SCAP folding remains intact.\n    - The SCAP-SREBP-2 interaction is intact.\n    - The MELADL COPII recognition motif on SCAP is intact.\n    - Golgi processing of the SREBP-2 precursor by Site-1 and Site-2 proteases is intact (contingent on ER-to-Golgi transport).\n- **Experimental Conditions:**\n    - No exogenous oxysterols are added.\n    - The concentration of cholesterol in the endoplasmic reticulum (ER) membrane, $[Ch]_{\\mathrm{ER}}$, is varied.\n    - The system is observed at steady state for each $[Ch]_{\\mathrm{ER}}$.\n- **Measurement:** The transcriptional output of SREBP-2 target genes is measured and denoted as $E([Ch]_{\\mathrm{ER}})$.\n- **Objective:** Predict the qualitative dependence of $E([Ch]_{\\mathrm{ER}})$ on $[Ch]_{\\mathrm{ER}}$ and identify the correct mechanism from the provided options.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated for validity based on scientific principles.\n\n1.  **Scientific Soundness:** The problem is based on the well-characterized SREBP pathway, a central mechanism for cellular cholesterol homeostasis. The roles of SREBP-2, SCAP, Insig, the ER, the Golgi, and the relevant proteases are described in a manner consistent with established biochemical and cell biological fact. The concept of a sterol-sensing domain (SSD) in SCAP and its function in cholesterol-dependent regulation is a cornerstone of this field. A mutation that abolishes cholesterol binding to SCAP is a valid and commonly used hypothetical (and experimental) construct to probe the pathway's logic.\n2.  **Well-Posedness:** The problem is well-posed. It defines a specific perturbation (a mutation with defined consequences) to a known biological system and asks for the resulting system behavior ($E([Ch]_{\\mathrm{ER}})$ as a function of $[Ch]_{\\mathrm{ER}}$). The initial conditions and constraints are clearly specified, allowing for a unique, deductive conclusion based on first principles.\n3.  **Objectivity:** The language is objective and precise. Crucially, the effects of the mutation are explicitly stated (e.g., binding abolished, other functions intact), removing ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, and objective. It contains no logical contradictions, scientific inaccuracies, or undefined terms. Therefore, the problem is **valid**. A solution will be derived.\n\n### Derivation from First Principles\nThe regulation of cholesterol biosynthesis is governed by the SREBP-2 pathway. We shall analyze the behavior of this pathway under the specified mutant condition.\n\n1.  **The Wild-Type Pathway (Reference):**\n    - At low $[Ch]_{\\mathrm{ER}}$, the SCAP-SREBP-2 complex is packaged into COPII vesicles, facilitated by the accessible MELADL motif on SCAP, and is transported from the ER to the Golgi apparatus.\n    - In the Golgi, SREBP-2 is sequentially cleaved by Site-1 Protease (S1P) and Site-2 Protease (S2P), releasing its N-terminal domain, a potent transcription factor designated nSREBP-2.\n    - nSREBP-2 translocates to the nucleus and activates target genes, leading to high transcriptional output, $E([Ch]_{\\mathrm{ER}}) \\to E_{\\max}$.\n    - At high $[Ch]_{\\mathrm{ER}}$, cholesterol binds to the sterol-sensing domain (SSD) of SCAP.\n    - This binding induces a conformational change in SCAP, promoting its high-affinity interaction with the ER-resident protein Insig.\n    - The resulting SCAP-Insig interaction has two effects: it masks the MELADL motif on SCAP, preventing COPII vesicle packaging, and it retains the entire SCAP-SREBP-2 complex in the ER.\n    - Consequently, SREBP-2 is not processed, nSREBP-2 is not generated, and target gene transcription is repressed, leading to low transcriptional output, $E([Ch]_{\\mathrm{ER}}) \\to E_{\\min}$.\n\n2.  **The Mutant Pathway (Problem Scenario):**\n    - The problem states that the mutation in SCAP's SSD **abolishes** its ability to bind cholesterol.\n    - The critical regulatory event in the wild-type pathway is the cholesterol-induced conformational change in SCAP that enables its binding to Insig.\n    - Since the mutant SCAP cannot bind cholesterol, it will never undergo this conformational change, regardless of how high $[Ch]_{\\mathrm{ER}}$ becomes.\n    - Lacking the cholesterol-dependent conformation, the mutant SCAP will be unable to bind to Insig.\n    - Without the formation of the SCAP-Insig retention complex, the MELADL motif on SCAP remains perpetually exposed.\n    - Therefore, the SCAP-SREBP-2 complex will be constitutively packaged into COPII vesicles and transported from the ER to the Golgi, irrespective of the cholesterol concentration $[Ch]_{\\mathrm{ER}}$.\n    - In the Golgi, SREBP-2 will undergo constitutive proteolytic processing, leading to a constant and maximal production of the active nSREBP-2 transcription factor.\n    - This will result in maximal, sustained activation of SREBP-2 target genes.\n    - The conclusion is that the transcriptional output, $E([Ch]_{\\mathrm{ER}})$, will be high and essentially constant, independent of the variable $[Ch]_{\\mathrm{ER}}$. Mathematically, $E([Ch]_{\\mathrm{ER}}) \\approx E_{\\max}$ for all values of $[Ch]_{\\mathrm{ER}}$.\n\n### Option-by-Option Analysis\n\n**A. $E([Ch]_{\\mathrm{ER}})$ decreases monotonically with increasing $[Ch]_{\\mathrm{ER}}$ (high at low $[Ch]_{\\mathrm{ER}}$, low at high $[Ch]_{\\mathrm{ER}}$), due to cholesterol-dependent ER retention of SCAP-SREBP-2 by Insig.**\nThis option describes the behavior of the *wild-type* system. It is incorrect because the problem specifies a mutant SCAP that cannot bind cholesterol. Without cholesterol binding to SCAP, there can be no cholesterol-dependent retention by Insig.\n**Verdict: Incorrect.**\n\n**B. $E([Ch]_{\\mathrm{ER}}) \\approx E_{\\max}$ and is essentially independent of $[Ch]_{\\mathrm{ER}}$, because loss of cholesterol sensing prevents Insig-mediated ER retention and allows constitutive ER-to-Golgi trafficking and proteolytic activation of SREBP-2.**\nThis option correctly identifies that the loss of cholesterol binding to SCAP prevents its interaction with Insig. This blockage of the retention mechanism leads to constitutive transport of SREBP-2 to the Golgi, constitutive processing, and therefore maximal, cholesterol-independent transcriptional output. This matches the derivation from first principles.\n**Verdict: Correct.**\n\n**C. $E([Ch]_{\\mathrm{ER}}) \\approx E_{\\min}$ and is essentially independent of $[Ch]_{\\mathrm{ER}}$, because SCAP cannot activate SREBP-2 without binding cholesterol.**\nThis reasoning is flawed. SCAP's role is to escort SREBP-2; its default state is to promote transport to the Golgi. Cholesterol binding does not \"activate\" this process; rather, it *inhibits* it by inducing retention. The absence of cholesterol binding leads to the a constitutively active transport process, not an inactive one.\n**Verdict: Incorrect.**\n\n**D. $E([Ch]_{\\mathrm{ER}})$ is high at low $[Ch]_{\\mathrm{ER}}$, partially reduced at intermediate $[Ch]_{\\mathrm{ER}}$, and strongly repressed only at very high $[Ch]_{\\mathrm{ER}}$, reflecting a right-shifted sterol dose–response via residual Insig-dependent retention.**\nThis would imply that the mutation only reduced the affinity of SCAP for cholesterol, rather than abolishing binding. The problem states that binding is *abolished*. Furthermore, while other regulatory inputs exist in the full biological system (e.g., oxysterols acting on Insig), the problem explicitly excludes them (\"No exogenous oxysterols are added\") and focuses on the direct effect of the SCAP mutation in response to cholesterol alone. Based on the strict premises, no residual regulation should occur.\n**Verdict: Incorrect.**\n\n**E. $E([Ch]_{\\mathrm{ER}})$ increases with increasing $[Ch]_{\\mathrm{ER}}$, because loss of feedback makes SREBP-2 more responsive to sterols.**\nThis is fundamentally incorrect. The SREBP-2 pathway is a negative feedback loop; increasing cholesterol *decreases* transcriptional output in the wild-type system. An increasing function is the opposite of the known regulatory logic. The loss of feedback should make the system *unresponsive* to the feedback signal (cholesterol), not more responsive.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "2550069"}, {"introduction": "The enzyme HMG-CoA reductase (HMGCR) is not only a key point of regulation but also the primary target for cholesterol-lowering statin drugs. This problem shifts our focus from conceptual pathway logic to quantitative enzyme kinetics, providing direct practice in applying the Michaelis-Menten framework to pharmacology. By calculating the apparent Michaelis constant ($K_{m,app}$) in the presence of a competitive inhibitor, you will gain a practical understanding of how these powerful drugs modify enzyme behavior at the active site [@problem_id:2550092].", "problem": "In the mevalonate pathway of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyzes the reduction of HMG-CoA to mevalonate using Nicotinamide Adenine Dinucleotide Phosphate (reduced form) (NADPH) as a co-substrate in a sequential ordered mechanism. Under conditions where the NADPH concentration is saturating, the rate law with respect to HMG-CoA reduces to a Michaelis–Menten form. Consider the following experimentally determined parameters at a fixed temperature and pH: the Michaelis constant for HMG-CoA is $K_{m,\\mathrm{HMG-CoA}} = 4.00\\,\\mu\\mathrm{M}$; the Michaelis constant for NADPH is $K_{m,\\mathrm{NADPH}} = 10.0\\,\\mu\\mathrm{M}$. A potent small-molecule inhibitor that binds competitively to the HMG-CoA site has an inhibition constant $K_{i} = 1.00\\,\\mathrm{nM}$ with respect to HMG-CoA. You perform initial-velocity measurements at saturating NADPH and add inhibitor at a free concentration $[I] = 10.0\\,\\mathrm{nM}$.\n\nStarting from the steady-state Michaelis–Menten framework and the definition of a competitive inhibitor that binds only to the free enzyme, derive the expression for the initial velocity as a function of $[S]$ and identify the apparent Michaelis constant for HMG-CoA in the presence of inhibitor. Then, compute the apparent Michaelis constant at $[I] = 10.0\\,\\mathrm{nM}$ given the parameters above. Round your answer to $3$ significant figures and express it in $\\mu\\mathrm{M}$.", "solution": "The problem as stated is subjected to validation.\n\nStep 1: Extract Givens\n- Enzyme: $3$-hydroxy-$3$-methylglutaryl-coenzyme A (HMG-CoA) reductase.\n- Substrate $S_1$: HMG-CoA.\n- Co-substrate $S_2$: Nicotinamide Adenine Dinucleotide Phosphate (reduced form), NADPH.\n- Reaction: HMG-CoA reductase catalyzes the reduction of HMG-CoA to mevalonate.\n- Mechanism: Sequential ordered.\n- Condition: The concentration of NADPH, $[S_2]$, is saturating.\n- Michaelis constant for HMG-CoA: $K_{m,\\mathrm{HMG-CoA}} = 4.00\\,\\mu\\mathrm{M}$.\n- Michaelis constant for NADPH: $K_{m,\\mathrm{NADPH}} = 10.0\\,\\mu\\mathrm{M}$.\n- Inhibitor: A potent small-molecule inhibitor.\n- Inhibition type: Competitive with respect to the HMG-CoA binding site.\n- Inhibition constant: $K_{i} = 1.00\\,\\mathrm{nM}$.\n- Free inhibitor concentration: $[I] = 10.0\\,\\mathrm{nM}$.\n\nStep 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is well-grounded in the principles of enzyme kinetics, specifically the Michaelis-Menten model and the mechanism of competitive inhibition. The enzyme HMG-CoA reductase and its role in cholesterol biosynthesis are fundamental concepts in biochemistry. The parameters and conditions are scientifically plausible.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary constants ($K_m$, $K_i$) and conditions ($[I]$, saturating NADPH) to derive the apparent Michaelis constant and calculate its numerical value. The instruction to assume saturating NADPH simplifies the bi-substrate kinetics into a pseudo-single-substrate model, which is a standard and valid approach.\n- **Objectivity**: The problem is stated using precise, objective scientific language.\n- **Conclusion**: The problem is valid. It is self-contained, scientifically sound, and permits a unique solution based on the provided data.\n\nStep 3: Verdict and Action\nThe problem is valid. A solution will be furnished.\n\nThe initial task is to derive the rate equation for a competitive inhibitor within the Michaelis-Menten framework. Let the enzyme be denoted by `$E$`, the substrate (HMG-CoA) by `$S$`, the inhibitor by `$I$`, and the enzyme-substrate complex by `$ES$`. The relevant equilibria and reactions are:\n1.  Enzyme-substrate binding and catalysis:\n    $$E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_{cat}}{\\longrightarrow} E + P$$\n2.  Enzyme-inhibitor binding (competitive inhibition, inhibitor binds only to free enzyme):\n    $$E + I \\underset{k_{-i}}{\\stackrel{k_i}{\\rightleftharpoons}} EI$$\n\nThe inhibitor dissociation constant is given by $K_i = \\frac{[E][I]}{[EI]} = \\frac{k_{-i}}{k_i}$.\nThe Michaelis constant is defined as $K_m = \\frac{k_{-1} + k_{cat}}{k_1}$.\nThe initial velocity of the reaction is given by $v_0 = k_{cat}[ES]$.\nThe total enzyme concentration, $[E]_t$, is conserved:\n$$[E]_t = [E] + [ES] + [EI]$$\nwhere $[E]$, $[ES]$, and $[EI]$ are the concentrations of free enzyme, enzyme-substrate complex, and enzyme-inhibitor complex, respectively.\n\nUnder the steady-state assumption, the concentration of the enzyme-substrate complex is constant, $\\frac{d[ES]}{dt} = 0$.\nThe rate of formation of `$ES$` is $k_1[E][S]$.\nThe rate of breakdown of `$ES$` is $k_{-1}[ES] + k_{cat}[ES] = (k_{-1} + k_{cat})[ES]$.\nAt steady state:\n$$k_1[E][S] = (k_{-1} + k_{cat})[ES]$$\n$$[E][S] = \\frac{k_{-1} + k_{cat}}{k_1} [ES] = K_m [ES]$$\nThus, the concentration of free enzyme can be expressed in terms of $[ES]$:\n$$[E] = \\frac{K_m [ES]}{[S]}$$\nFrom the definition of the inhibition constant, we can express the concentration of the enzyme-inhibitor complex in terms of $[E]$:\n$$[EI] = \\frac{[E][I]}{K_i}$$\nSubstituting the expression for $[E]$:\n$$[EI] = \\frac{K_m [ES]}{[S]} \\frac{[I]}{K_i}$$\nNow, we substitute the expressions for $[E]$ and $[EI]$ into the total enzyme concentration equation:\n$$[E]_t = \\frac{K_m [ES]}{[S]} + [ES] + \\frac{K_m [ES]}{[S]} \\frac{[I]}{K_i}$$\nFactoring out $[ES]$:\n$$[E]_t = [ES] \\left( 1 + \\frac{K_m}{[S]} + \\frac{K_m [I]}{[S]K_i} \\right)$$\n$$[E]_t = [ES] \\left( 1 + \\frac{K_m}{[S]} \\left( 1 + \\frac{[I]}{K_i} \\right) \\right)$$\nSolving for $[ES]$:\n$$[ES] = \\frac{[E]_t}{1 + \\frac{K_m}{[S]} \\left( 1 + \\frac{[I]}{K_i} \\right)}$$\nThe initial velocity is $v_0 = k_{cat}[ES]$. Substituting the expression for $[ES]$:\n$$v_0 = \\frac{k_{cat}[E]_t}{1 + \\frac{K_m}{[S]} \\left( 1 + \\frac{[I]}{K_i} \\right)}$$\nWe define the maximum velocity as $V_{max} = k_{cat}[E]_t$.\n$$v_0 = \\frac{V_{max}}{1 + \\frac{K_m}{[S]} \\left( 1 + \\frac{[I]}{K_i} \\right)}$$\nTo obtain the standard Michaelis-Menten form, we multiply the numerator and denominator by $[S]$:\n$$v_0 = \\frac{V_{max}[S]}{[S] + K_m \\left( 1 + \\frac{[I]}{K_i} \\right)}$$\nThis is the derived expression for the initial velocity. By comparing this to the standard Michaelis-Menten equation without inhibitor, $v_0 = \\frac{V_{max}[S]}{K_m + [S]}$, we can identify the apparent Michaelis constant, $K_{m,app}$, in the presence of the competitive inhibitor. The term occupying the position of $K_m$ is:\n$$K_{m,app} = K_m \\left( 1 + \\frac{[I]}{K_i} \\right)$$\nThis expression demonstrates that a competitive inhibitor increases the apparent Michaelis constant by a factor of $\\left(1 + \\frac{[I]}{K_i}\\right)$, while $V_{max}$ remains unchanged.\n\nNow, we compute the numerical value of $K_{m,app}$.\nThe given parameters are:\n- $K_{m} = K_{m,\\mathrm{HMG-CoA}} = 4.00\\,\\mu\\mathrm{M}$\n- $K_{i} = 1.00\\,\\mathrm{nM}$\n- $[I] = 10.0\\,\\mathrm{nM}$\n\nBefore substituting the values, we must ensure consistent units for $K_i$ and $[I]$. Both are given in $\\mathrm{nM}$, so their ratio can be computed directly.\nThe dimensionless factor is:\n$$\\frac{[I]}{K_i} = \\frac{10.0\\,\\mathrm{nM}}{1.00\\,\\mathrm{nM}} = 10.0$$\nThe problem specifies that the inhibitor concentration $[I] = 10.0\\,\\mathrm{nM}$ (three significant figures) and the inhibition constant $K_i = 1.00\\,\\mathrm{nM}$ (three significant figures). Their ratio is thus $10.0$, which has three significant figures.\n\nNow, we calculate $K_{m,app}$:\n$$K_{m,app} = K_{m,\\mathrm{HMG-CoA}} \\left( 1 + \\frac{[I]}{K_i} \\right)$$\n$$K_{m,app} = (4.00\\,\\mu\\mathrm{M}) \\times (1 + 10.0)$$\nThe number `$1$` is an exact integer. The sum $1 + 10.0 = 11.0$. The precision of the sum is determined by the term with the fewest decimal places, which is $10.0$ (one decimal place). The result $11.0$ correctly has one decimal place and three significant figures.\n$$K_{m,app} = (4.00\\,\\mu\\mathrm{M}) \\times (11.0)$$\nThe product of $4.00$ (three significant figures) and $11.0$ (three significant figures) must be reported to three significant figures.\n$$K_{m,app} = 44.0\\,\\mu\\mathrm{M}$$\nThe apparent Michaelis constant for HMG-CoA in the presence of $10.0\\,\\mathrm{nM}$ of the competitive inhibitor is $44.0\\,\\mu\\mathrm{M}$.", "answer": "$$\\boxed{44.0}$$", "id": "2550092"}]}